Key Insights

Highlights

Success Rate

83% trial completion

Published Results

85 trials with published results (10%)

Research Maturity

307 completed trials (37% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

7.7%

65 terminated out of 839 trials

Success Rate

82.5%

-4.0% vs benchmark

Late-Stage Pipeline

6%

54 trials in Phase 3/4

Results Transparency

28%

85 of 307 completed with results

Key Signals

85 with results83% success65 terminated

Data Visualizations

Phase Distribution

625Total
Not Applicable (191)
Early P 1 (18)
P 1 (171)
P 2 (191)
P 3 (47)
P 4 (7)

Trial Status

Completed307
Recruiting213
Unknown114
Active Not Recruiting66
Terminated65
Not Yet Recruiting50

Trial Success Rate

82.5%

Benchmark: 86.5%

Based on 307 completed trials

Clinical Trials (839)

Showing 20 of 20 trials
NCT06952504Phase 3RecruitingPrimary

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT07725159Not ApplicableCompletedPrimary

Comparison of Lee-Huang Point and Umbilical Entry for Laparoscopic Success in Endometrial Cancer Patients

NCT07578649Phase 3Not Yet Recruiting

Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

NCT06974110Phase 1Recruiting

Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

NCT05797168Phase 1Recruiting

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT04291612RecruitingPrimary

Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

NCT03564340Phase 1Recruiting

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

NCT05208762Phase 1Recruiting

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

NCT07524322Phase 1Recruiting

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

NCT07124000Recruiting

DESTINY-PANTUMOUR04

NCT06340568Phase 3RecruitingPrimary

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT07714070Phase 2Not Yet Recruiting

Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia

NCT06293898Phase 1RecruitingPrimary

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

NCT07419841Phase 1Recruiting

A Phase 1 Study of the Safety and Tolerability of CTX-10726

NCT07702799Not ApplicableRecruitingPrimary

Low-Residue Diet Versus Rectal Enema Before Laparoscopic Surgery for Endometrial Cancer

NCT05799274Phase 1Recruiting

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

NCT04104776Phase 1Recruiting

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

NCT05123482Phase 1Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

NCT06409052RecruitingPrimary

Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women

NCT06906341Phase 2Recruiting

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Scroll to load more

Research Network

Activity Timeline